Organizing Pharmaceutical Innovation: From Science-based Knowledge Creators to Drug-oriented Knowledge Brokers

Creativity and Innovation Management

Volumn 14, Issue 3, 2005, Pages 233-245

  Gassmann, Oliver ^a   Reepmeyer, Gerrit ^b  

^a UNIVERSITY OF ST GALLEN   (Switzerland)

^b The Sanford C Bernstein Co Center for Leadership and Ethics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84959106513     PISSN: 09631690     EISSN: 14678691     Source Type: Journal    
DOI: 10.1111/j.1467-8691.2005.00344.x     Document Type: Article

References (44)

1. Agarwal, S., Desai, S., Holcomb, M.M. and Oberoi, A. (2001) ‘Unlocking the Value in Big Pharma’, The McKinsey Quarterly 2, 65–73.
2. Albertini, S. and Butler, J. (1995) ‘R&D Networks in a pharmaceutical company: Some implications for human resource management’, R&D Management, 25(4), 377–93.
3. Beckmann, C. and Fischer, J. (1994) ‘Einflussfaktoren auf die Internationalisierung von Forschung und Entwicklung in der Chemischen und Pharmazeutischen Industrie’, Zeitschrift für Betriebswirtschaftliche Forschung, 46(7/8), 630–57.
4. Boerner, C.S.R. (2002) New product development organization and performance: theory and evidence from the pharmaceutical industry. Dissertation at the University of California at Berkeley. UMI Number: 3063299. Spring 2002.
5. Brach, M.A. and Paxson, D.A. (2001) ‘A gene to drug venture: poisson options analysis’, R&D Management, 31(2), 203–214.
6. Buchanan, I.P.M. (2002): R&D Collaborations – A partners’ perspective. Vertex Pharmaceuticals. Presentation, 27 February, Zurich.
7. Bunch, P.R. and Schacht, A.L. (2002) ‘Modeling resource requirements for pharmaceutical R&D’, Research Technology Management, Jan–Feb, 48–56.
8. Cardinal, L.B. and Hatfield, D.E. (2000) ‘Internal knowledge generation: the research laboratory and innovative productivity in the pharmaceutical industry’, Journal of Engineering and Technology Management, 17, 247–71.
9. Cassimon, D., Engelen, P.J., Thomassen, L. and Van Wouwe, M. (2004) ‘The valuation of a NDA using a 6-fold compound option’, Research Policy, 33, 41–51.
10. Chesbrough, H.W. (2003) Open Innovation: The New Imperative for Creating and Profiting from Technology. Harvard Business School Press, Boston MA.
11. Cockburn, I.M., Henderson, R.M. and Stern, S. (2000) ‘Untangling the origins of competitive advantage’, Strategic Management Journal, 21, 1123–45.
12. Creswell, J. (1994) Research Design-Qualitative & Quantitative Approaches. Sage Publications, Thousand Oaks CA.
13. DiMasi, J. (2001) ‘Tufts center for the study of drug development pegs costs of a new prescription drug at $802 million’. Press release, Tufts University, 30 November.
14. Drews, J. (1989) ‘Research in the pharmaceutical industry’, European Management Journal, 7(1), pp. 23–30.
15. Gassmann, O. and Von Zedtwitz, M. (1998) ‘Organization of Industrial R&D on a Global Scale R&D Management, 28(3), 147–61.
16. Gassmann, O. and Von Zedtwitz, M. (1999) ‘New concepts and trends in international R&D organization’, Research Policy, 28, 231–50.
17. Gassmann, O. and Von Zedtwitz, M. (2003) ‘Trends and determinants of managing virtual R&D teams’, R&D Management, 33(3), 243–62.
18. Gassmann, O., Reepmeyer, G. and Von Zedtwitz (2004) Leading Pharmaceutical Innovation – Trends and Drivers for Growth in the Pharmaceutical Industry. Springer, Berlin.
19. Halliday, R.G., Drasdo, A.L., Lumley, C.E. and Walker, S.R. (1997) ‘The allocation of resources for R&D in the world's leading pharmaceutical companies’, R&D Management, 27(1), pp. 63–77.
20. Henderson, R. (1994) ‘Managing Innovation in the Information Age’, Harvard Business Review, 72(Jan–Feb), 100–5.
21. Jones, O. (2000) ‘Innovation management as a post-modern phenomenon: The outsourcing of pharmaceutical R&D’, British Journal of Management, 11, 341–56.
22. Jones, O., Conway, S. and Steward, F. (2000) ‘Introduction: Social interaction and organisation change’. In: Jones, O., Conway, S. and Steward, F. (eds.), Social interaction and organisational change: Aston perspectives on innovation networks. Imperial College Press, London.
23. KPMG (2002) Pharmaceuticals – Global Insights. KPMG Report by John Morris, Chair of the Europe, Middle East, South Asia, Africa Chemicals & Pharmaceuticals Practice, February.
24. Kuemmerle, W. (1999) ‘Foreign direct investment in industrial research in the pharmaceutical and electronics industries-results from a survey of multinational firms’, Research Policy, 28(2–3), 179–94.
25. Lehman Brothers (1999) Pharmaceutical Outsourcing Digest, 3 December.
26. Loch, C.H. and Bode-Greuel, K. (2001) ‘Evaluating growth options as sources of value for pharmaceutical research projects’, R&D Management, 31(2), 231–48.
27. McGrath, R.G. and Nerkar, A. (2004) ‘Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms’, Strategic Management Journal, 25, 1–21.
28. Needleman, P. (2001) ‘From a twinkle in the eye to a blockbuster drug’, Research Technology Management, Nov–Dec, 38–41.
29. Pfeiffer, P. (2000) Sicherung von F&E-Kompetenz in multinationalen Pharmaunternehmen. Dissertation at the University of St. Gallen, Dissertation-No. 2362.
30. PhRMA (2003) Pharmaceutical Research and Manufacturers of America, PhRMA Annual Membership Survey. PhRMA, Washington, DC.
31. PhRMA (2004) Pharmaceutical Industry Profile 2004. PhRMA, Washington, DC.
32. Pisano, G., Shan, W. and Teece, D. (1988) ‘Joint ventures and collaboration in the biotechnology industry’. In: Mowery, D.C. (ed.), International collaborative ventures in US manufacturing. Ballinger, Cambridge, pp. 183–222.
33. Powell, W.W., Koput, K.W. and Smith-Doerr, L. (1996) ‘Interorganizational collaboration and the locus of innovation: networks of learning in biotechnology’, Administrative Science Quarterly, 41(1), 116–45.
34. Reuters (2002) Pharmaceutical innovation – an analysis of leading companies and strategies. Reuters Business Insight, Healthcare, London, UK.
35. Reuters (2003) The blockbuster drug outlook to 2007: Identifying, creating and maintaining the pharmaceutical industry's growth drivers. Reuters Business Insight, Healthcare, London, UK.
36. Tapon, F. and Thong, M. (1999) ‘Research collaborations by mulit-national research oriented pharmaceutical firms: 1988–1997’, R&D Management, 29(3), 219–31.
37. Teoh, P-L. (1994) ‘Speed to global market success: an empirical prediction of new product success in the ethical pharmaceutical industry’, European Journal of Marketing, 11, pp. 29–49.
38. Thurow, L. (1996) The future of capitalism. New York: W. Morrow and Co.
39. Tidd, J. (1997) ‘Complexity, networks and learning: Integrative themes for research on the management of innovation’, International Journal of Innovation Management, 1(1), 1–19.
40. Völker, R. (2001) ‘Planung und Steuerung von Entwicklungsprojekten in der Pharmabranche’. In: Gassmann, O., Kobe, C. and Voit, E. (eds.), High-Risk-Projekte. Springer, Berlin, pp. 231–47.
41. Von Zedtwitz, M. and Gassmann, O. (2002) Market versus technology drive in R&D internationalization: four different patterns of managing research and development. Research Policy, 31(4), 569–88.
42. Whittaker, E. and Bower, D.J. (1994) ‘A Shift to External Alliances for Product Development in the Pharmaceutical Industry’, R&D Management, 24(3), 249–60.
43. Yeoh, P-L. and Roth, K. (1999) ‘An empirical analysis of sustained advantage in the US pharmaceutical industry: impact of firm resources and capabilities’, Strategic Management Journal, 20, 637–53.
44. Yin, R.K. (1988) Case Study Research: Design and Methods. Newbury Park, London.